Recorded $5.8 million in nonrecurring expenses during Q4 related to headcount reductions and asset write-offs during the ...
OPKO reshaped BioReference after selling its oncology assets to Labcorp, trimming headcount ~29% and refocusing on core clinical lab services and the 4Kscore; management expects improved margins and ...
OPKO Health, Inc. (NASDAQ:OPK) Q3 2025 Earnings Call Transcript October 29, 2025 OPKO Health, Inc. beats earnings expectations. Reported EPS is $0.03, expectations were $-0.02. Operator: Good ...
Following the announcement, Labcorp’s shares edged down 0.9%, finishing at $275.40 on Monday. Labcorp maintains a robust pipeline of potential acquisitions that align with its financial strategy and ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The Burlington-based lab giant ...
BURLINGTON, N.C. and MIAMI, Sept. 15, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, and OPKO Health ...
CFO Logal provided full-year 2025 guidance: total revenue between $640 million and $660 million; revenue from services of $405 million to $425 million, including $95 million to $105 million from ...
The Deal: The Greenberg Traurig shareholders led a large team of attorneys who represented Opko Health Inc. in its $1.47 billion acquisition of Bio-Reference Laboratories Inc. Opko, a Miami-based ...
A New Jersey laboratory which had parts of its business acquired by Labcorp earlier this month has laid off 81 employees. BioReference Health terminated the employees from its headquarters in Elmwood ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results